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Introduction
Ageing is associated with the increasing stiffness of the large ar-
teries. Studies have shown that increased arterial stiffness, which 
is a clinical parameter that reflects the degree of arterial ageing, is a 
significant predictor of cardiovascular disease independent from 
blood pressure and other cardiovascular risk factors. Arterial stiff-
ness is mainly associated with a patient’s age and is also significant-
ly influenced by other conditions that induce oxidative stress. Recent 
studies revealed the molecular mechanism as well as pathologic 
findings of the arterial ageing processes. This article will cover the 
pathophysiology of arterial ageing, recent evidence regarding the 
treatment of arterial aging and novel treatment targets that are in-
vestigated.
Ageing and Vascular Changes
Structural changes
Arteriosclerosis is the pathological term that is used frequently to 
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describe arterial ageing. However, arteriosclerosis is a broad defini-
tion encompassing atherosclerosis, Mönckeberg medial calcific scle-
rosis, and arteriolosclerosis.1-3) However, none of these terms can des-
cribe exactly all of the pathological changes of the ageing arteries, 
for example, age related medial degeneration and sclerosis.4) Com-
pared to healthy young vessel, aged vessels are characterized by 
increased reactive oxygen species and vascular inflammation that 
results in endothelial dysfunction. Subsequently, vascular smooth 
muscle cells (VSMC) migrate into the subendothelial space then 
proliferate and cause an accumulation of collagen and proteogly-
can in the intima.5) On the other hand, the number of VSMCs in the 
media layer decreases due to apoptosis. Moreover, elastin is degrad-
ed in the media and the space is replaced by collagen accumulation 
and calcification. The elastin degradation of the media layer is one 
of the major pathological findings of arterial ageing and is a major 
reason for the increased stiffening of the large arteries with ageing. 
Various pathways including inflammatory cytokines, adhesion mo-
lecules, matrix metalloproteinases (MMPs) and transforming growth 
factor-β are involved in the ageing process of the major arteries.6)7)
Functional changes
The major functional change that occurs with arterial ageing is 
the loss of distensibility. Functional and structural mechanisms ac-
count for the decreased distensibility and increased stiffness. The 
functional deterioration of the aged arteries are characterized by 
endothelial dysfunction8)9) with significant decrease in the acetylch-
oline induced nitric oxide dependent vasodilation.10) Also, the num-
ber of receptors in the vessel and the affinity decreases and conse-
quent decrement of β2-receptor dependent vasodilation occurs.11) 
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As the large arteries stiffen the velocity of the pulse wave increas-
es. The measurement of this velocity, called the pulse wave velocity 
(PWV), is a common surrogate marker for assessing the degree of 
arterial ageing. The loss of large arterial distensibility is associated 
with increased forward amplitude, which will increase the systolic 
pressure. Also, increasing PWV will result in the early return of the re-
flected wave and increased augmented pressure. This will subsequ-
ently lead to increased systolic blood pressure and pulse pressure 
which lead to more stiffening and thickening of arterial walls in a 
vicious cycle.11) Even though increased arterial stiffness is a major 
mechanism for the pathogenesis of systolic hypertension in the 
elderly, arterial stiffness itself is an independent risk factor for the 
major cardiac events independent from blood pressure.12) Studies 
have demonstrated a significant increase in cardiovascular events 
in patients with carotid femoral PWV of 12 meter/sec or higher.13) As 
such, the European Society of Hypertension classifies a person with 
carotid-femoral PWV higher than 12 meter/sec as a high risk hy-
pertensive patient.14)15)
Risk Factors That Are Associated with Acceleration 
of Arterial Ageing
Studies have shown that although ageing is the strongest predic-
tor of arterial stiffness, the degree of arterial stiffness can be accel-
erated by various risk factors such as hypertension, smoking, high 
salt intake, dyslipidemia, diabetes mellitus and biomarkers such as 
high sensitive C-reactive protein (hs-CRP). Among these risk factors, 
this review article will focus on hypertension, the neurohumoral me-
chanism and inflammation. 
Hypertension
Although age is the most important contributing factor to arterial 
ageing, its effect is largely influenced by other clinical factors in-
cluding hypertension, diabetes mellitus, dyslipidemia or vascular 
inflammation. Benetos et al.16) reported that high blood pressure, 
high pulse rate and high serum creatinine are independent predic-
tors of arterial stiffness after the analysis of 483 individuals who 
were examined twice over a 6 years period. In the hypertensive pa-
tients, the progression of arterial stiffness measured by PWV ch-
ange was significantly higher compared to normotensive patients.13) 
The mechanism could be explained by increased oxidative stress,17) 
vascular inflammation,18) endothelial dysfunction19) and activation of 
the renin-angiotensin aldosterone system (RAAS)20) that is charac-
teristic of hypertension. Studies have shown that controlling blood 
pressure significantly suppresses the progression of arterial stiffness 
and the suppression of progression regarding arterial stiffness has 
been demonstrated to be associated with significant improvement 
in cardiovascular prognosis.21) As the activation of the RAAS path-
way is important in the pathogenesis of arterial ageing, antihyper-
tensive drugs that block RAAS may be more effective in reducing ar-
terial stiffness beyond the blood pressure lowering effect. This has 
been demonstrated in several, small scale studies. Takami et al.22) 
studied the change of brachial-ankle PWV (baPWV) at the baseline 
and 3 months after drug treatment with 80 mg of valsartan (angio-
tensin receptor blocker, ARB), 2-4 mg of temocapril (angiotensin 
converting enzyme inhibitor, ACEI), 10 mg cilnidipine (L, N type cal-
cium channel blocker, CCB) or 20 mg of Nifedipine (L type dihydro-
pyridine CCB) by the random allocation of 76 patients older than 65 
years of age. Interestingly, valsartan, temocapril, and cilnidpine re-
duced the baPWV value considerably whereas nifedipine hardly did 
even though there was no difference in the change of blood pres-
sure between the groups (Fig. 1). Among the anti-hypertensive drugs, 
valsartan demonstrated the strongest effect in reducing the PWV. 
Similarly, Munakata et al.23) randomly assigned 41 hypertensive 
patients into two groups and treated them with valsartan or nifedi-
pine for 3 months. The reduction of the PWV value was only observ-
ed in the valsartan group whereas there was no difference in the ch-
ange of blood pressure between the groups. Both studies comment-
ed that nifedipine, which is dihydropyridine CCB, did not reduce the 
PWV because the drug increased heart rate which is directly pro-
portional to PWV. The limitation of both studies was the fact that 
as the PWV value was measured just 3 months after treatment, the 
reduction of PWV may be due to passive destiffening due to blood 
Fig. 1. Changes in the brachial-ankle pulse wave velocity (ΔbaPWV) be-
tween baseline and 3 months after the administration of each agent. Statis-
tically significant reductions of baPWV compared with the baseline values 
were seen in the valsartan, temocapril, and cilnidipine groups. ΔbaPWV was 
lowest in the nifedipine CR group. ΔbaPWV was significantly higher in the 
valsartan group than in the other groups. Mean±SD. One-way ANOVA with 
Scheffe’s test. *p<0.01. Reprinted from Takami T, Shigemass M. Hypertens Res 
2003;26:609-14 with permission.22) ANOVA: analysis of variance, CR: con-
trolled-release.
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pressure decrease rather than a long term benefit on the structure 
of the arteries. However, the fact that there was a significant differ-
ence despite a similar reduction in blood pressure suggests a po-
tential beneficial effect of RAAS blockade for reducing arterial stif-
fness. Also, recent studies have demonstrated evidences to suggest 
that, in addition to the blood pressure lowering effect, ARB or ACEI 
have a protective effect against arterial ageing by anti-oxidation, 
anti-inflammation and improvement of the endothelial function by 
RAAS inhibition.24)25) Larger studies that could demonstrate whether 
or not the differential effect on PWV may affect long term cardiac 
prognosis is needed. 
Renin-angiotensin-aldosterone system 
Traditionally, RAAS has been known to affect the arteriole and 
cause systemic vasoconstriction, but recent studies have revealed 
that RAAS can also change the structure of large arteries by chang-
ing the important composition such as collagen and elastin.26) Also, 
neurohumoral modification on the large artery causing endothelial 
cell dysfunction has been known to accelerate arterial ageing.27) Re-
cent evidence suggests that excess aldosterone may have a detri-
mental effect on arterial ageing. In a study done of 438 hyperten-
sive patients who underwent PWV measurement and assessment 
of the aldosterone-renin ratio (ARR), ARR of at least 20 with a se-
rum aldosterone level higher than 12 ng/dL had significantly high-
er PWV values compared to hypertensive patients with an ARR 
value lower than 20 after adjusting for contributing factors (Fig. 2). 
Multiple linear regression revealed that aldosterone is significantly 
associated with PWV.28)
Recent evidence suggests that aldosterone blockade using spi-
ronolactone reduces arterial stiffness independent from blood pres-
sure. In a study by Edwards et al.29) 112 chronic kidney disease stage 
2 or 3 patients with well controlled blood pressure who were tak-
ing RAAS blockade at baseline were administered with either spi-
ronolactone 25 mg or a placebo. The follow-up PWV measurement 
at the 40th week of treatment demonstrated that patients who were 
administered with spironolactone showed a significant reduction 
in PWV and augmentation index independent from blood pressure 
reduction (Fig. 3). Aldosterone, through the activation of the miner-
alocorticoid receptor, may act to increase arterial inflammation and 
fibrosis. As such, administration of spironolactone may reduce ar-
terial stiffness and retard arterial ageing through the reduction of 
arterial inflammation and fibrosis.30)31)
Vascular inflammation 
Vascular inflammation is a well-known contributing factor for the 
pathogenesis of arterial ageing. Necropsy studies done in aged hu-
man thoracic aortas demonstrate increased levels of angiotensin 
converting enzyme, angiotensin II, angiontensin receptor type 1 
MMPs and MCP-1 compared to the young aortas, suggesting the li-
kelihood for the significant role of inflammation in the pathogen-
esis of vascular stiffening.32) The activation of the MCP-1/CCR2 pa-
Fig. 2. Hypertensive patients with ARR ≥20 and serum aldosterone ≥12 
ng/dL showed significantly higher PWV values compared with patients 
with ARR <20. Reproduced from Park S, Kim JB, Shim CY, et al. J Hypertens 
2007;25:1279-83 with permission.28) hfPWV: heart to femoral pulse wave 
velocity, ARR: aldosterone to renin ratio.
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Fig. 3. Changes of pulse wave velocity and augmentation index was measured 40 weeks after administration of 25 mg spironolactone or placebo in 112 
chronic kidney disease patients who were previously taking RAAS blockade. A: spironolactone group (Spiro) resulted in a significant reduction of PWV (-0.8±1.0 
m/s vs. -0.1±0.9 m/s, p<0.01).  B: augmentation index (auglx) was significantly reduced in the spironolactone treated group compared with the placebo 
(-5.2±6.1% vs. -1.4±5.9%, p<0.05). Reproduced from Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. J Am Coll Cardiol 2009;54:505-512 with 
permissioin.29) *p<0.01, †p<0.05. PWV: pulse wave velocity. 
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thway, which has been demonstrated to have a significant role in 
mediating vascular inflammation and remodeling, further stimu-
lates vascular inflammation, increases the expression of cell adhe-
sion molecules, increases the secretion of MMP, amplifies the activi-
ty of other cytokines and increases VSMC migration.33-35) Also, stu-
dies have demonstrated that inflammatory cytokines stimulate the 
local production of C reactive protein by VSMCs.36)37) CRP, which is 
well known to be a marker of systemic inflammation, has been de-
monstrated to have an active role in promoting vascular inflamm-
ation and reducing endothelial function.38-40) CRP has been shown 
to be associated with endothelial dysfunction, increased cytokine 
expression, such as monocyte chemoattractant protein-1, and en-
dothelial cell adhesion molecules.41) Recent studies have demonst-
rated a significant association of hs-CRP and arterial stiffness.42)43) A 
study by Chae et al.44) demonstrated that in a normotensive popul-
ation, increase in hs-CRP is associated with the future development 
of hypertension, suggesting a role for systemic inflammation in the 
pathogenesis of vascular remodeling and hypertension.
The importance of inflammation in the pathogenesis of arterial 
ageing can be readily seen in patients suffering from chronic inflam-
matory disease such as rheumatoid arthritis. Studies have clearly 
demonstrated that patients with chronic inflammatory disease have 
increased PWV compared to control subjects in the similar age gr-
oup and that patients with systemic inflammatory disease have ac-
celerated arterial ageing that is independent from age and blood 
pressure.45-47) In a study by Galarraga et al.48) twenty six rheumatoid ar-
thritis patients treated with tumor necrosis factor alpha antagonist 
showed significant attenuation of the augmentation index after 2 
and 4 months of treatment which were not observed in 122 patients 
treated with conventional disease-modifying anti-rheumatic drug 
regimens. This demonstrates that reduction of the systemic in-
flammatory process may reduce inflammation in the arteries and 
subsequently retard the progression of arterial ageing. From the stu-
dies that have been done regarding the pathogenesis of arterial 
ageing, we propose that risk factors such as ageing, hypertension, 
dyslipidemia, and diabetes all act through the common pathway of 
increased oxidative stress and vascular inflammation that leads to 
adverse vascular remodeling and accelerated arterial ageing. 
Molecular Mechanism of Arterial Ageing
A disease associated with a proven genetic defect provides us 
with insight into the pathogenesis, molecular mechanism and pos-
sible therapeutic target of the disease. Arterial ageing exhibits such 
a disease in the Hutchinson Gilford Progeria syndrome (HGPS). The 
molecular defect caused by a single gene defect in HGPS is well de-
fined and provides numerous of clues for research on the arterial 
ageing process. HGPS is caused by a point mutation in position 1824 
of the LMNA gene, replacing cytosine with thymin, resulting in the 
subsequent deletion of 150 base pairs in Exon 11 which is an im-
A   B  
Fig. 4. Hutchinson Gilford Progeria syndrome is caused by a single base 
change of C to T at position of 1824 of the LMNA gene (B). This mutation 
does not change the encoded amino acid (Glycine) but results in the acti-
vation of a cryptic splice site 150 nucleotides upstream of the usual exon 
11-to-12 splice junction. As a result, progerin lacks the second cleavage site 
which is found on prelamin A protein of normal population (A) and thus re-
mains permanently farnesylated. Reprined from Kovascic JC, Moreno P, 
Hachinski V, Nabel EG, Fuster V. Circulation 2011;123:1650-60 with permis-
sion.49) LMNA: lamin A and C.
Fig. 5. Statins suppress farnesyl pyrophosphate which is substrate for the 
farnesylation by HMG-CoA inhibition. Farnesyl transferase inhibitors report-
edly suppress arterial ageing in vivo by reducing farnesylated prelamin A 
(=Progerin) accumulation. Rapamycin increase the clearance of farnesylated 
prelamin A by enhancing the autophage mechanism.
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portant target sequence of the excision enzyme Zmpste24/FACE1. 
As a result, the farnesylated C terminus cannot be removed from the 
prelamin and the protein, which is a major structural component of 
the nuclear lamina along with lamin C, cannot be integrated into 
the nucleus (Fig. 4).49) This will eventually result in nuclear disruption, 
epigenetic and genetic dysregulation, dysfunction of VSMC prolif-
eration and increased apoptosis which will result in accelerated ath-
erosclerosis and premature ageing. For reasons unknown, the aging 
process is most affected in the VSMC, resulting in the affected pa-
tients dying at an average age of 13 years, mostly due to cerebro-
vascular disease or myocardial infarct.50) Although progerin does 
not accumulate in the normal ageing process, as oxidative stress in-
creases the expression of Zmpste24/FACE1 which excises the farne-
sylated C terminus from the prelamin A protein decreases.51) The re-
sultant prelamin accumulation and lamin disruption results in pa-
thologic findings in the vasculature that are similar to those of HG-
PS.51)52) The results from this study show that any process that in-
creases oxidative stress, such as the clinical risk factors of acce-
lerated arterial ageing, may act to inhibit the expression of Zmpste 
24/FACE1 and promote arterial ageing. The farnesyl transferase in-
hibitor and geranyl-geranyl transferase inhibitor are a class of drugs 
that inhibit the prenylation of the C terminus of prelamin and stud-
ies have shown that the administration of these drugs suppress 
vascular ageing in-vivo.53) Currently, clinical trials are ongoing to 
demonstrate the efficacy of the farnesyl transferase inhibitor in 
patients with HGP syndrome.53-55) A well-known pleiotropic effect 
of HMG-CoA reductase inhibitors is the inhibition of the synthesis 
of farnesyl pyrophosphate or geranyl-geranyl pyrophosphate which 
is an important substrate for progerin formation.56) Some studies 
reported that statins suppress the progression of arterial stiffening 
in humans.56)57) More recently, rapamycin, which is an inhibitor of 
the mammalian target of rapamycin, reportedly may enhance the 
clearance of mutated lamin by the autophage mechanism (Fig. 5).58) 
Although rapamycin itself may be too toxic to administer systemati-
cally, it provides an attractive target to explore for discovering the 
possible therapeutic target of arterial ageing.
In summary, although arterial ageing is naturally observed in the 
normal ageing process, various conditions including hypertension, 
dyslipidemia, diabetes mellitus, cytokines, the genetic condition or 
inflammation enhance oxidative stress and consequent cellular se-
nescence, and telomere shortening or a lamin A dependent nuclear 
defect ultimately accelerate the arterial aging process (Fig. 6).
Conclusion 
Arterial ageing can be described as age related medial degenera-
tion and sclerosis. Aged arteries are associated with endothelial dys-
function, intima thickening, elastin degradation of the media layer 
and accumulation of collagen and proteoglycans in the media layer. 
The increase in the stiffness of the large arteries will result in in-
creased systolic blood pressure and is independently associated with 
an increased risk of cardiovascular disease. Various conditions that 
enhance oxidative stress and cellular senescence, through the inhi-
bition of the expression of Zmpste24/FACE1, cause the accumula-
tion of prelamin and nuclear defects which will accelerate the arte-
rial ageing processes. Recently, in vivo studies regarding the efficacy 
of drugs to reduce the laminopathy such as the farnesyl transferase 
inhibitor or rapamycin have been promising and provide new insight 
into the mechanism and treatment of arterial ageing in the future. 
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